Simultaneous fluorescence immunophenotyping and Her-2/neu genotyping (FICTION) in breast carcinoma candidates to target therapy

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 4, 2012, Pages 413-420

  Gatta, Luisa Benerini ^a   Incardona, Paolo ^a   Cadei, Moris ^a   Grigolato, Piergiovanni ^a   Simoncelli, Sabrina ^a   Balzarini, Piera ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

breast cancer; FICTION; Her 2 neu; target therapy

Indexed keywords

CYTOKERATIN 19; CYTOKERATIN AE1; CYTOKERATIN AE3; CYTOKERATIN ANTIBODY;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER DIAGNOSIS; CHROMOSOME 17; CLINICAL ARTICLE; CYTOSKELETON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MOLECULARLY TARGETED THERAPY; ONCOGENE NEU; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENTINEL LYMPH NODE METASTASIS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATINS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; RECEPTOR, ERBB-2;

EID: 84862866936     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31823fb322     Document Type: Article

References (25)

1. Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol. 2011;23:37-43. Review.
2. Kurosumi M. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer. Breast Cancer. 2009;16:284-287. Review.
3. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
4. Gutierrez C, Schiff R. HER2: Biology, Detection, and Clinical Implications. Arch Pathol Lab Med. 2011;135:55-62.
5. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. College of American Pathologists. Arch Pathol Lab Med. 2009;133: 611-612.
6. Ahmed SS, Iqbal J, Thike AA, et al. HER2/neu revisited: quality and interpretive issues. J Clin Pathol. 2011;64:120-124.
7. Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol. 2009;131:678-682.
8. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. American Society of Clinical Oncology; College of American Pathologists. J Clin Oncol. 2007;25:5418-5425. (Pubitemid 350232218)
9. Weber-Matthiesen K, Winkemann M, Muller-Hermelink A, et al. Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem. 1992;40:171-175.
10. Martinez-Ramirez A, Cigudosa JC, Maestre L, et al. Simultaneous detection of the immunophenotypic markers and genetic aberrations on routinely processed paraffin sections of lymphoma samples by means of the FICTION technique. Leukemia. 2004;18:348-353. (Pubitemid 38240053)
11. Martin-Subero I, Siebert R, Calasanz MJ. Conventional and multicolor FICTION as tools for the interdisciplinar study of hematological neoplasms. An Sist Sanit Navar. 2002;25:289-304. Spanish.
12. Campos M, Prior C, Warleta F, et al. Phenotypic and genetic characterization of circulation tumor cell by combining immuno-magnetic selection and FICTION techniques. J Histochem Cyto-chem. 2008;56:667-675. (Pubitemid 351842420)
13. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403-439. Review. (Pubitemid 34535443)
14. Alix-Panabieres C, Vendrell JP, Slijper M, et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res. 2009;11:R39.
15. Fleming ID, Cooper JS, Henson DE, et al. American Joint Committee on the Classification of Ductal Carcinoma in situ. 5th ed. Philadelphia: Lippincott-Raven; 1997.
16. Hermanek P, Hutter R, Sobin Lh, et al. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. 4th ed. Berlin: Springer-Verlag; 1997.
17. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636. (Pubitemid 34983222)
18. Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res. 2011;17:952-958.
19. Yosepovich A, Avivi C, Bar J, et al. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially. Isr Med Assoc J. 2010; 12:353-356.
20. Killeen JL, Ortega-Lopez A, Shaha J, et al. Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype. Breast Cancer Res Treat. 2006;98:99-108. (Pubitemid 44050784)
21. Brugmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19:203-211.
22. Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132:539-548. Review.
23. Bzorek M Sr, Petersen BL, Hansen L. Simultaneous phenotyping and genotyping (FICTION-methodology) on paraffin sections and cytologic specimens: a comparison of 2 different protocols. Appl Immunohistochem Mol Morphol. 2008;16:279-286. (Pubitemid 351589546)
24. Zhang Y, Siebert R, Matthiesen P, et al. Feasibility of simultaneous fluorescence immunophenotyping and fluorescence in situ hybridization study for the detection of estrogen receptor expression and deletions of the estrogen receptor gene in breast carcinoma cell lines. Virchows Arch. 2000;436:271-275. (Pubitemid 30168686)
25. Korac P, Jones M, Dominis M, et al. Application of the FICTION technique for the simultaneous detection of immunophenotype and chromosomal abnormalities in routinely fixed, paraffin wax embedded bone marrow trephines. J Clin Pathol. 2005;58: 1336-1338. (Pubitemid 41752786)